Acute Myeloid Leukemia in RemissionPhase 2NCT07163793
Pilot Study of Reduced Venetoclax Exposure
A Phase 2 study testing Azacitidine, Decitabine and Venetoclax in people with Acute Myeloid Leukemia in Remission, run by Northwell Health at 1 site in United States.
Trial summary
Pilot Study of Reduced Venetoclax Exposure Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Acute Myeloid Leukemia in Remission
- What is being tested?
- Azacitidine, Decitabine and Venetoclax
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 41 participants
- Where
- 1 siteUnited States
- Study dates
- 26 Aug 2025to Feb 2028
- Phase
- Phase 2
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Stated willingness to comply with all study procedures and availability for the duration of the study
- Ability to take oral medication and be willing to adhere to the study regimen
- Diagnosed by current WHO or ICC criteria with Acute Myeloid Leukemia and treated for initial induction therapy with one of two regimens:
- 5-Azacitidine administered subcutaneously at a dose of 75mg/m2/day X 7 days in combination with VEN (21-28 days/cycle)
- Decitabine administered intravenously at a dose of 20mg/m2/day administered in combination with VEN (21-28 days/cycle)
- Achieving morphological CR/CRi by bone marrow biopsy with <5% blasts within 3 cycles. See Appendix 2 for definitions.
Show all 9Show fewer
- ECOG 0-3
- Patient must be able to understand and sign informed consent and additional study documents
- On C1D1 of trial, patient must have count recovery with ANC >1000, platelets > 50, Hemoglobin > 7.7 and without transfusion support for 7 days.
Who cannot join
- Treatment with another investigational drug
- Use of growth factor (G-CSF) within the last 14 days prior to C1D1 of trial treatment.
- Subject has received treatment prior to induction with the following:
- Prior hypomethylating agent or BCL-2 inhibitor for either AML or MDS other than for induction prior to enrollment.
- Prior CAR-T cell therapy. iii. Experimental or investigational drug therapy for 14 days prior to study entry leukemia-directed therapies.
- Subject has:
- Acute promyelocytic leukemia (APL) with t(15;17). ii. Presence of t(9;22) given the potential indication for concurrent tyrosine kinase therapy.
- Known active CNS involvement with AML.
Trial locations and contacts
1 site in 1 country.
United States1 site
Zuckerberg Cancer Center
New Hyde Park, New York, 11042
About this study
Official title: A Pilot Study of Reduced Venetoclax Exposure in Patients With Acute Myeloid Leukemia in Complete Remission
Pilot Study of Reduced Venetoclax Exposure
Read the detailed description
A pilot single-arm clinical trial is proposed to assess the primary objective: the tolerability of 14-day Venetoclax cycles in acute myeloid leukemia (AML) patients who have achieved remission and are ineligible for intensive treatment. Participants in the study will transition to a maintenance regimen that reduces the Venetoclax dosage to 14 days per cycle while continuing the hypomethylating agent (HMA) used during induction. Treatment cycles will occur every 28 days. Participants will continue treatment on study until experiencing a grade 4 cytopenic event lasting more than 7 days, an adverse event requiring regimen modification, relapse, or death.
Our primary hypothesis posits that AML patients receiving Venetoclax for 14 days per cycle will exhibit improved treatment tolerability with a reduced rate of grade 4 cytopenia compared to historical data from the VIALE A trial.
- Conditions
- Acute Myeloid Leukemia in Remission
- Being tested
- Azacitidine, Decitabine, Venetoclax
- Keywords
- AML
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
AzacitidineDrug
Also called Vidaza
Given Day 1-7 with Venetoclax Day 1-14 every 28 days until off study
DecitabineDrug
Also called Dacogen
Given Day 1-5 with Venetoclax Day 1-14 every 28 days until off
VenetoclaxDrug
Also called Venclexta, Venclyxto
Venetoclax up to 400mg a day on Day 1-14 every 28 days until off in combination with Azacitidine or Decitabine
| Study group | Role | What they receive |
|---|---|---|
| Azacytadine + Venetoclax | Active comparator | Not described Receives: Drug: Azacitidine; Drug: Venetoclax |
| Decitabine + Venetoclax | Active comparator | Not described Receives: Drug: Decitabine; Drug: Venetoclax |
What is being measured
The primary outcome is the main question the study is designed to answer.
Venetoclax Tolerability Rate
Tolerability rate defined as the proportion of patients who do not experience grade 4 neutropenia (per the CTCAE v5.0) for over 7 continuous days within the first three cycles of maintenance therapy (90 days).
Patient will be evaluated on Day 1 of each cycle. Laboratory studies of prior cycle will be reviewed on that day to identify if patient had >7 continuous days of cytopenia.
Measured: 12 months
Secondary outcomes (10)
Evaluation of Event-Free Survival (EFS)
EFS: Time from treatment-to-treatment discontinuation, relapse, death of any cause, or lost to follow up (Lost to follow up defined as missing scheduled appointment with no response to 3 phone calls and 1 certified letter).
Measured: 12 months
Time to Detriment
Time to detriment defined as time to meaningful change in the EORTC-QLQ-C30. A meaningful change is defined as a decrease by at least 10 points from their baseline evaluation
The EORTC-QLQ0-C30 will be filled out by patient on Day 1 of every cycle for the first 12 cycles of maintenance therapy.
Measured: 48 months
Number of pRBC transfusion
Number of pRBC transfusion received while on trial therapy.
Number of platelet transfusion received while on trial therapy.
Number of transfusions to be described per patient year.
Data collected on Day 1 of every cycle.
Measured: 48 months
Evaluate Number of Hospital Admissions
To be evaluated at time of trial therapy discontinuation or 12 cycles of therapy, whichever occurs first.
Measured: 12 months
Rate of adverse events/toxicities
dverse events/Toxicities related to treatment.
List of adverse events/toxicities expected listed in Section 8.
Measured: 48 months
Evaluation of Relapse-Free Survival (RFS)
RFS: Time from treatment initiation to relapse, death, or lost to follow up (Lost to follow up defined as missing scheduled appointment with no response to 3 phone calls and 1 certified letter).
Measured: 12 months
Evaluation of Overall Survival (OS)
OS: Time to death or lost to follow up (Lost to follow up defined as missing scheduled appointment with no response to 3 phone calls and 1 certified letter)
Measured: 12 months
Evaluate Number of Days Admitted
To be evaluated at time of trial therapy discontinuation or 12 cycles of therapy, whichever occurs first.
Measured: 12 months
Evaluate Number of Unanticipated lab appointments
To be evaluated at time of trial therapy discontinuation or 12 cycles of therapy, whichever occurs first.
Measured: 12 months
Evaluate Number of Unanticipated clinic visits
To be evaluated at time of trial therapy discontinuation or 12 cycles of therapy, whichever occurs first.
Measured: 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Sep 2025
- Study start26 Aug 2025
- Primary completionOct 2026 (estimated)
- Study completionFeb 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Acute Myeloid Leukemia in RemissionStudies of the same condition, open and under way.
- More trials run by Northwell HealthThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 41 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Northwell Health
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Boiclair Stephanie, MD, Principal investigator, Northwell Health
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07163793
- Sponsor's protocol ID
- 24-0579
- Status last verified
- Oct 2026
- First submitted
- 7 Aug 2025
- Last updated
- 8 Oct 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 8 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Pilot Study of Reduced Venetoclax Exposure in Patients With Acute Myeloid Leukemia in Complete Remission
- ClinicalTrials.gov ID
- NCT07163793
- Acronym / sponsor ID
- 24-0579
- Conditions
- Acute Myeloid Leukemia in Remission
- Keywords
- AML
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 41 participants (estimated)
- Lead sponsor
- Northwell HealthUniversity, hospital or other
- Study start
- 26 Aug 2025 (actual)
- Primary completion
- Oct 2026 (estimated)
- Study completion
- Feb 2028 (estimated)
- First posted
- 9 Sep 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Pilot Study of Reduced Venetoclax Exposure
Detailed description
A pilot single-arm clinical trial is proposed to assess the primary objective: the tolerability of 14-day Venetoclax cycles in acute myeloid leukemia (AML) patients who have achieved remission and are ineligible for intensive treatment. Participants in the study will transition to a maintenance regimen that reduces the Venetoclax dosage to 14 days per cycle while continuing the hypomethylating agent (HMA) used during induction. Treatment cycles will occur every 28 days. Participants will continue treatment on study until experiencing a grade 4 cytopenic event lasting more than 7 days, an adverse event requiring regimen modification, relapse, or death.
Our primary hypothesis posits that AML patients receiving Venetoclax for 14 days per cycle will exhibit improved treatment tolerability with a reduced rate of grade 4 cytopenia compared to historical data from the VIALE A trial.
Study design
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Azacytadine + Venetoclax | Active comparator | Drug: Azacitidine, Drug: Venetoclax |
| Decitabine + Venetoclax | Active comparator | Drug: Decitabine, Drug: Venetoclax |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (9 listed)
- Stated willingness to comply with all study procedures and availability for the duration of the study
- Ability to take oral medication and be willing to adhere to the study regimen
- Diagnosed by current WHO or ICC criteria with Acute Myeloid Leukemia and treated for initial induction therapy with one of two regimens:
- Achieving morphological CR/CRi by bone marrow biopsy with <5% blasts within 3 cycles. See Appendix 2 for definitions.
- ECOG 0-3
Key exclusion criteria (8 listed)
- Treatment with another investigational drug
- Use of growth factor (G-CSF) within the last 14 days prior to C1D1 of trial treatment.
- Subject has received treatment prior to induction with the following:
- Subject has:
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| AzacitidineAlso: VidazaGiven Day 1-7 with Venetoclax Day 1-14 every 28 days until off study | Drug | Azacytadine + Venetoclax |
| DecitabineAlso: DacogenGiven Day 1-5 with Venetoclax Day 1-14 every 28 days until off | Drug | Decitabine + Venetoclax |
| VenetoclaxAlso: Venclexta, VenclyxtoVenetoclax up to 400mg a day on Day 1-14 every 28 days until off in combination with Azacitidine or Decitabine | Drug | Azacytadine + Venetoclax, Decitabine + Venetoclax |
Primary outcome
Venetoclax Tolerability Rate
Time frame: 12 months
Tolerability rate defined as the proportion of patients who do not experience grade 4 neutropenia (per the CTCAE v5.0) for over 7 continuous days within the first three cycles of maintenance therapy (90 days). Patient will be evaluated on Day 1 of each cycle. Laboratory studies of prior cycle will be reviewed on that day to identify if patient had >7 continuous days of cytopenia.
10 secondary outcomes
Evaluation of Event-Free Survival (EFS)
Time frame: 12 months
Time to Detriment
Time frame: 48 months
Number of pRBC transfusion
Time frame: 48 months
Evaluate Number of Hospital Admissions
Time frame: 12 months
Rate of adverse events/toxicities
Time frame: 48 months
Evaluation of Relapse-Free Survival (RFS)
Time frame: 12 months
Evaluation of Overall Survival (OS)
Time frame: 12 months
Evaluate Number of Days Admitted
Time frame: 12 months
Evaluate Number of Unanticipated lab appointments
Time frame: 12 months
Evaluate Number of Unanticipated clinic visits
Time frame: 12 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Oct 2026.
- Individual participant dataSharing planned: No
Related trials for Acute Myeloid Leukemia in Remission
RecruitingPhase 2
Personalized NK Cell Therapy in CBT
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia
Active, not recruitingObservational study
Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant
Hematopoietic/Lymphoid Cancer, Accelerated Phase Chronic Myelogenous Leukemia
Active, not recruiting
Haploidentical Hematopoietic Cell Transplantation Using TCR Alpha/Beta and CD19 Depletion
Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia in Remission
Active, not recruitingPhase 2
Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia
RecruitingPhase 1
Ziftomenib Maintenance Post Allo-HCT
Acute Myeloid Leukemia, Acute Myeloid Leukemia in Remission
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Boiclair Stephanie, MD principal investigator
Northwell Health
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Azacitidine, Decitabine and Venetoclax in people with Acute Myeloid Leukemia in Remission, run by Northwell Health at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 9 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 8 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Venetoclax Tolerability Rate (time frame: 12 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Oct 2026; AzTrials last refreshed its copy on 6 Nov 2026.